Meniscus Tear

0
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Arthrex
ArthrexCA - Santa Barbara
2 programs
Nanoscopic partial meniscectomyN/A1 trial
SoftStitch™N/A1 trial
Active Trials
NCT05617807RecruitingEst. Dec 2024
NCT05491564UnknownEst. Oct 2024
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
EuflexxaN/A1 trial
Active Trials
NCT01256788Terminated34Est. Apr 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ArthrexSoftStitch™
ArthrexNanoscopic partial meniscectomy
Ferring PharmaceuticalsEuflexxa

Clinical Trials (3)

Total enrollment: 34 patients across 3 trials

NCT05491564ArthrexSoftStitch™

SoftStitch™ for All-Inside Meniscal Repair: Comparative Analysis of Patient Reported Outcome Measures

Start: Jul 2023Est. completion: Oct 2024
N/AUnknown
NCT05617807ArthrexNanoscopic partial meniscectomy

Outcomes of the Nanoscopic Partial Meniscectomy Versus Standard Arthroscopic Partial Meniscectomy

Start: Dec 2022Est. completion: Dec 2024
N/ARecruiting

Post-op Treatment With Hyaluronic Acid Injections

Start: Sep 2010Est. completion: Apr 201434 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 34 patients
2 companies competing in this space